NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its first-quarter revenues grew 10 percent year over year, driven by a sharp uptick in diagnostic services that was somewhat offset by a decline in genetic analysis product sales and services.

The San Diego-based molecular diagnostics firm brought in total revenues of $14.9 million for the three-month period ended March 31, compared to $13.5 million for the first quarter of 2011. It fell short of Wall Street's consensus estimate of $16.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.